Inovio Stock Sinks As FDA Pushes Back On Accelerated Approval For Rare Disease Drug

Benzinga_recent_news2025-12-30

Inovio Pharmaceuticals Inc. (NASDAQ:INO) stock fell Monday after the U.S. Food and Drug Administration accepted the company’s Biologics License Application (BLA) for INO-3107 but raised concerns tied ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2595341407?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/29/FDA.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2025-12-30 00:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595341407","market":"sh","top_or_hot":-1,"title":"Inovio Stock Sinks As FDA Pushes Back On Accelerated Approval For Rare Disease Drug","media":"Benzinga_recent_news","content":"<div>\n<p>Inovio Pharmaceuticals Inc. (NASDAQ:INO) stock fell Monday after the U.S. Food and Drug Administration accepted the company’s Biologics License Application (BLA) for INO-3107 but raised concerns tied ...</p>\n\n<a href=\"https://www.benzinga.com/news/fda/25/12/49614410/inovio-stock-sinks-as-fda-pushes-back-on-accelerated-approval-for-rare-disease-drug\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inovio Stock Sinks As FDA Pushes Back On Accelerated Approval For Rare Disease Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInovio Stock Sinks As FDA Pushes Back On Accelerated Approval For Rare Disease Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-30 00:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/fda/25/12/49614410/inovio-stock-sinks-as-fda-pushes-back-on-accelerated-approval-for-rare-disease-drug><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Inovio Pharmaceuticals Inc. (NASDAQ:INO) stock fell Monday after the U.S. Food and Drug Administration accepted the company’s Biologics License Application (BLA) for INO-3107 but raised concerns tied ...</p>\n\n<a href=\"https://www.benzinga.com/news/fda/25/12/49614410/inovio-stock-sinks-as-fda-pushes-back-on-accelerated-approval-for-rare-disease-drug\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4583","symbol_name":"猴痘概念","start_time":0,"source_url":"https://www.benzinga.com/news/fda/25/12/49614410/inovio-stock-sinks-as-fda-pushes-back-on-accelerated-approval-for-rare-disease-drug","article_id":"2595341407","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/29/FDA.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/25/12/49614410/inovio-stock-sinks-as-fda-pushes-back-on-accelerated-approval-for-rare-disease-drug","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2595341407","pubTimestamp":1767027540,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Inovio stock down as FDA accepts BLA for INO-3107, but notes insufficient info for accelerated approval pathway. Meeting requested.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4583":"猴痘概念","BK4568":"美国抗疫概念","BK4139":"生物科技","INO":"伊诺维奥制药"},"translate_title":"FDA推迟加速批准罕见病药物，Inovio股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INO":1},"content_text":"Inovio Pharmaceuticals Inc. (NASDAQ:INO) stock fell Monday after the U.S. Food and Drug Administration accepted the company’s Biologics License Application (BLA) for INO-3107 but raised concerns tied to the accelerated approval pathway.\nThe biotechnology company focused on developing and commercializing DNA medicines said that the FDA accepted the company’s BLA for INO-3107 for review as a potential treatment for adults with Recurrent Respiratory Papillomatosis (RRP). The review classification designated by the FDA is Standard.\nRRP is a rare, benign (noncancerous) disease caused by the Human Papillomavirus, leading to wart-like tumors in the respiratory tract, most commonly the larynx (voice box).\nAlso Read: European And US Vaccine Stocks Are Under Pressure – Here’s WHy\nThe FDA assigned INO-3107 a Prescription Drug User Fee Act (PDUFA) review goal date of October 30, 2026.\nThe FDA has indicated that it is not currently planning to hold an advisory committee meeting to discuss this application.\nInovio filed its BLA under the accelerated approval pathway.\nThe FDA, in the file acceptance letter, noted as a potential review issue its preliminary conclusion that the company has not submitted adequate information to justify eligibility for the accelerated approval pathway.\nInovio continues to believe that INO-3107 provides a meaningful therapeutic benefit over existing treatments and fulfills the criteria for accelerated approval.\nInovio plans to request a meeting with the FDA to discuss the next steps to remain eligible under the accelerated approval program.\nInovio is not currently planning to seek approval for INO-3107 under the traditional pathway.\nThe BLA is supported by data from a Phase 1/2 trial evaluating INO-3107 in adult patients with RRP who had two or more surgeries in the year prior to treatment.\nLong-term durability data from a retrospective trial of the original trial participants were also included in the BLA filing, demonstrating that the majority of evaluable patients continued to see clinical benefit in the second twelve-month period after treatment, without additional dosing.\nINO Price Action: Inovio Pharmaceuticals shares were down 24.38% at $1.73 at the time of publication on Monday, according to Benzinga Pro data.\nRead Next:\nPhoto by Tada Images via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2595341407","isCrawlerRequest":true}